Form 8-K · Current Report · Filed 2026-04-30
Halozyme Appoints New Chief Financial Officer
Halozyme Therapeutics, Inc. announced on April 30, 2026, the appointment of Darren Snellgrove as its new Chief Financial Officer, effective June 8, 2026. Snellgrove, previously with Johnson & Johnson, will be responsible for leading the company's financial operations and strategy. His compensation includes an annual salary of $670,000, a sign-on bonus of $350,000, and equity awards totaling $7.2 million. The current Interim CFO, David Ramsay, will transition to an advisory role during the changeover period.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001159036-26-000053
- CIK
- 0001159036
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$63.06
Next session
+1.4%
Since filing
+74.8%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, HALO insiders reported 3 Form 4 transactions — net selling of $189K.
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.